S
Zodix
Study
Academic Library
Search
Shelves
Open access
Sign in
Search or jump to…
⌘K
Qiu Li · Study
Home
/
Author
Qiu Li
4 works
· latest 2020
· 1 institutions
cluster: provisional
ORCID 0000-0002-5158-3838
Follow
Suggest an ORCID correction
h-index
4
i10
4
Citations
220
Works here
4
19
20
Most cited in this library
Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer
2019 · 75 citations
Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives
2020 · 50 citations
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
2019 · 48 citations
Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores
2019 · 47 citations
Works
4 shown
Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives
Frontiers in Oncology
·
2020
·
5 authors
·
Open access
50
citations
Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores
Lung Cancer
·
2019
·
2 authors
47
citations
Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer
Lung Cancer
·
2019
·
6 authors
75
citations
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
Journal of Medical Economics
·
2019
·
3 authors
·
Open access
48
citations